HAE250117C95000
- 0.95
- 0.000.00%
Haemonetics Newsroom
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025
Barrington Reaffirms Their Buy Rating on Haemonetics (HAE)
Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Macroeconomic Woes, FX Headwind Drag NEOG Stock Down
Haemonetics Announces EVP Josep Llorens' Retirement
Here's Why You Should Add HAE Stock to Your Portfolio Now
Earnings Grew Faster Than the Favorable 12% CAGR Delivered to Haemonetics (NYSE:HAE) Shareholders Over the Last Three Years
Down -11.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Haemonetics (HAE)
Haemonetics: Strong Market Position and Attractive Investment Opportunity Amid Growth in Plasma and Hospital Segments
Should You Continue to Hold TMO Stock in Your Portfolio?
Are Investors Undervaluing Haemonetics (HAE) Right Now?
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Haemonetics Initiated at Overweight by JP Morgan
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Terns Pharmaceuticals (TERN)
Express News | Haemonetics Corp : JP Morgan Initiates Coverage With Overweight Rating; Price Target $116
Haemonetics' Strategic Divestment to Boost Core Apheresis Focus and Long-term Growth
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $108
Haemonetics Corporation: Strategic Divestment and Innovation Drive Buy Rating With $125 Target
Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?
TMO Stock to Gain From the New Additions to CTS Portfolio of Products